Cite
Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients
MLA
Rieko Isoda, et al. “Impact of LDLR and PCSK9 Pathogenic Variants in Japanese Heterozygous Familial Hypercholesterolemia Patients.” Atherosclerosis, vol. 289, Oct. 2019, pp. 101–08. EBSCOhost, https://doi.org/10.1016/j.atherosclerosis.2019.08.004.
APA
Rieko Isoda, Kiminori Hosoda, Mariko Harada-Shiba, Atsushi Takahashi, Yoshihiro Miyamoto, Mika Hori, Masatsune Ogura, Cheol Son, Suguru Yamamoto, Hiroaki Masuda, & Naotaka Ohta. (2019). Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients. Atherosclerosis, 289, 101–108. https://doi.org/10.1016/j.atherosclerosis.2019.08.004
Chicago
Rieko Isoda, Kiminori Hosoda, Mariko Harada-Shiba, Atsushi Takahashi, Yoshihiro Miyamoto, Mika Hori, Masatsune Ogura, et al. 2019. “Impact of LDLR and PCSK9 Pathogenic Variants in Japanese Heterozygous Familial Hypercholesterolemia Patients.” Atherosclerosis 289 (October): 101–8. doi:10.1016/j.atherosclerosis.2019.08.004.